FDA's bi­o­log­ics chief Pe­ter Marks pre­views ac­cel­er­at­ed ap­proval guid­ance

The FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search is plan­ning to re­lease some cru­cial guid­ance soon for CRISPR and gene ther­a­py de­vel­op­ers on plat­form tech­nolo­gies, ac­cel­er­at­ed ap­provals for rare dis­eases, and po­ten­tial­ly in the “not-too-dis­tant fu­ture,” a plat­form tech­nol­o­gy guid­ance specif­i­cal­ly for genome edit­ing, CBER Di­rec­tor Pe­ter Marks said Tues­day in an Al­liance for a Stronger FDA we­bi­nar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER